<DOC>
	<DOCNO>NCT01316276</DOCNO>
	<brief_summary>The purpose study evaluate long term safety tolerability Arikayce Cystic Fibrosis patient . This long-term , open-label , multi-cycle extension study enroll subject successfully complete study TR02-108 , compliant study protocol , meet list study discontinuation criterion . The safety tolerability Arikayce evaluate approximately 2 year .</brief_summary>
	<brief_title>Extension Study Arikayce Cystic Fibrosis ( CF ) Patients With Chronic Pseudomonas Aeruginosa Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Pseudomonas Infections</mesh_term>
	<mesh_term>Amikacin</mesh_term>
	<criteria>Key Written inform consent assent Subject complete study TR02108 , compliant study protocol Women childbearing potential must agree use reliable method contraception duration study Key Subject meet list criterion study drug discontinuation protocol TR02108 . Abnormal laboratory assessment include LFT ( ≥ 3× ULN ) , serum creatinine ( &gt; 2× ULN ) ANC ( &lt; 1000 ) . Psychotic , addictive disorder limit ability provide inform consent comply study requirement . History alcohol , medication illicit drug abuse within 6 month prior consent . Smoking tobacco substance within 6 month prior consent anticipate inability refrain smoking throughout study</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Cystic Fibrosis</keyword>
	<keyword>Respiratory Infections</keyword>
	<keyword>Pulmonary Cystic Fibrosis</keyword>
	<keyword>CFTR</keyword>
	<keyword>Anti-bacterial Agent</keyword>
</DOC>